Research Atlas · source screening

Oritavancin

An attributable first-pass index of PubMed records whose titles name this governed identity. Records are sorted by publication date, not by evidence strength. Inclusion does not establish efficacy, safety, or a clinical indication.

Title-search results

245

Shown with stable PMIDs

25

Search recorded

2026-09-26

Source: NCBI PubMed / MEDLINE · exact query: "Oritavancin"[Title] · up to 25 recent title matches per identity. Each result links to its PubMed record.

1. Oritavancin safety: a real-world pharmacovigilance study of the FAERS database.

   Front Cell Infect Microbiol · 2026 · PMID 42609687 · DOI 10.3389/fcimb.2026.1798934

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

2. Oritavancin as consolidation or suppressive therapy in infective endocarditis and device-related infections: real-world experience with therapeutic drug monitoring.

   JAC Antimicrob Resist · 2026 Aug · PMID 42500354 · DOI 10.1093/jacamr/dlag150

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

3. Precision redosing of oritavancin: A population pharmacokinetic framework to optimize long-term therapy for complex gram-positive infections.

   Int J Antimicrob Agents · 2026 Jul 29 · PMID 42526659 · DOI 10.1016/j.ijantimicag.2026.107943

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

4. Correction: Alarcia-Lacalle et al. Oritavancin Multiple Dosing for Complex Infections: A Pharmacokinetic/Pharmacodynamic Simulation Study. Pharmaceutics 2026, 18, 628.

   Pharmaceutics · 2026 Jul 24 · PMID 42654162 · DOI 10.3390/pharmaceutics18080912

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

5. Oritavancin as sequential therapy for vancomycin-resistant Enterococcus faecium prosthetic valve endocarditis: a case report.

   J Chemother · 2026 May 22 · PMID 42175558 · DOI 10.1080/1120009X.2026.2674359

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

6. Oritavancin Multiple Dosing for Complex Infections: A Pharmacokinetic/Pharmacodynamic Simulation Study.

   Pharmaceutics · 2026 May 20 · PMID 42198319 · DOI 10.3390/pharmaceutics18050628

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

7. Could oritavancin be a promising alternative treatment for staphylococcal bone and joint infections? Insights from the determination of oritavancin minimum inhibitory concentrations in a collection of clinical isolates from the French National reference centre for staphylococci.

   Eur J Clin Microbiol Infect Dis · 2026 May · PMID 41493744 · DOI 10.1007/s10096-025-05383-3

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

8. Off-label use of oritavancin: a case series on clinical effectiveness, bed-day savings and cost benefits.

   JAC Antimicrob Resist · 2026 Apr · PMID 41852956 · DOI 10.1093/jacamr/dlag036

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

9. Oritavancin in Complicated Bloodstream Infections and Endocarditis in Spain and Italy (ORIBAC Study): A Retrospective Multicenter Observational Study.

   Infect Dis Ther · 2026 Apr · PMID 41764708 · DOI 10.1007/s40121-026-01314-7

   Source metadata only · evidence grade unassigned · scientific conclusions pending review

10. Evaluating oritavancin for Gram-positive infections: a systematic review of on-label and off-label use.

    Drugs Context · 2026 · PMID 41891114 · DOI 10.7573/dic.2025-9-4

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

11. Extrapolation of oritavancin PK/PD targets to inform therapeutic drug monitoring: a systematic review.

    J Antimicrob Chemother · 2026 Mar 4 · PMID 41914554 · DOI 10.1093/jac/dkag117

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

12. Oritavancin as rescue therapy in severe methicillin-resistant Staphylococcus aureus pneumonia: A case report.

    Respir Med Case Rep · 2026 · PMID 41847142 · DOI 10.1016/j.rmcr.2026.102393

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

13. Oritavancin for Gram-Positive Bone and Joint Infections: A Comprehensive Review of the Literature.

    Antibiotics (Basel) · 2026 Feb 19 · PMID 41750523 · DOI 10.3390/antibiotics15020226

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

14. An inoperable mediastinal infection involving vascular graft treated with weekly oritavancin as chronic suppressive therapy. A case report with pharmacokinetic data.

    J Antimicrob Chemother · 2026 Feb 2 · PMID 41700900 · DOI 10.1093/jac/dkag013

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

15. Medical source control with oritavancin in complicated gram-positive bacterial infections: A case series.

    Int J Infect Dis · 2025 Dec · PMID 41072854 · DOI 10.1016/j.ijid.2025.108111

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

16. Oritavancin for Treatment of Osteomyelitis: A Systematic Review and Meta-Analysis of Observational Studies.

    Pharmacotherapy · 2025 Nov · PMID 41224240 · DOI 10.1002/phar.70072

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

17. Comparative Analysis of Adverse Drug Reactions Between Oritavancin Diphosphate and Oritavancin-HPβCD Using FAERS Data.

    Hosp Pharm · 2025 Nov 1 · PMID 41185880 · DOI 10.1177/00185787251381580

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

18. Oritavancin in LVAD related infections - a chance for shortening therapy and improving outcomes.

    BMC Infect Dis · 2025 Oct 21 · PMID 41120906 · DOI 10.1186/s12879-025-11692-x

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

19. Oritavancin in a patient with recurrent endocarditis by Enterococcus faecalis: a new therapeutic option?

    J Antimicrob Chemother · 2025 Oct 3 · PMID 40625289 · DOI 10.1093/jac/dkaf215

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

20. A Comparative Review of the Pharmacology of Dalbavancin and Oritavancin for Gram-Positive Infections: Birds of a Feather or Apples and Oranges?

    Infect Dis Ther · 2025 Oct · PMID 40903703 · DOI 10.1007/s40121-025-01215-1

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

21. Oritavancin a Therapeutic Option for Periprosthetic Joint Infections in Selected Cases: A Comprehensive Review.

    Pharmaceuticals (Basel) · 2025 Aug 18 · PMID 40872608 · DOI 10.3390/ph18081217

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

22. The Use of Oritavancin as Consolidation Therapy for Infective Endocarditis Caused by Enterococcus spp.

    Open Forum Infect Dis · 2025 Aug · PMID 40799789 · DOI 10.1093/ofid/ofaf416

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

23. Unveiling the effect of chemical degradation on cyclic lipoglycopeptide Oritavancin using Orbitrap mass spectrometry.

    J Pharm Biomed Anal · 2025 Aug 1 · PMID 40081309 · DOI 10.1016/j.jpba.2025.116745

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

24. Oritavancin for the Treatment of Staphylococcus aureus Bacteremia-A Retrospective Single-arm Cohort Study.

    Open Forum Infect Dis · 2025 Jul · PMID 40657166 · DOI 10.1093/ofid/ofaf333

    Source metadata only · evidence grade unassigned · scientific conclusions pending review

25. Are Oritavancin and Dalbavancin More Cost Effective for Outpatient Parenteral Antimicrobial Therapy at a Veterans Affairs Medical Center?

    Fed Pract · 2025 Jun · PMID 40832670 · DOI 10.12788/fp.0571

    Source metadata only · evidence grade unassigned · scientific conclusions pending review